Apogee Therapeutics, Inc. entered into Agreement and Plan of Merger with Andor LLC, Andor Merger Co., and AbbVie Inc. valued at $135.11 per Share (effective 2026-06-18).
“On June 18, 2026, Apogee Therapeutics, Inc. (the “Company” or “Apogee”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Andor LLC, a Delaware limited liability company and a wholly owned subsidiary of Guarantor (“Parent”), Andor Merger Co., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and solely for the limited purposes set forth therein, AbbVie Inc., a Delaware corporation (“Guarantor” or “AbbVie”).”
Material Agreements
Apogee Therapeutics, Inc. entered into IL-31R Discovery Agreement with Paragon Therapeutics, Inc. (effective 2026-06-17).
“On June 17, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an antibody discovery agreement with Paragon Therapeutics, Inc. (“Paragon,” and the antibody discovery agreement between the Company and Paragon, the “IL-31R Discovery Agreement”).”
Material Agreements
Apogee Therapeutics, Inc. entered into IL-31R License Agreement with Paragon Therapeutics, Inc. valued at up to $23.25 million (effective 2026-06-17).
“On June 17, 2026, contemporaneously with the execution of the IL-31R Discovery Agreement, the Company entered into a license agreement with Paragon (the “IL-31R License Agreement”).”
Shareholder Votes
Apogee Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-09 meeting.
“The compensation of our named executive officers as disclosed in the Proxy Statement was approved on a non-binding, advisory basis as follows: Votes For Votes Against Abstentions Broker Non-Votes 54,324,725 633,959 246,567 1,795,532”
Shareholder Votes
Apogee Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-09 meeting.
“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows: Votes For Votes Against Abstentions 56,960,778 1,361 38,644”
Shareholder Votes
Apogee Therapeutics, Inc. shareholders approved Election of Class III directors at the 2026-06-09 meeting.
“The following Class III director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Mark C. McKenna 53,689,547 1,515,704 1,795,532 Jennifer Fox 52,895,552 2,309,699 1,795,532 William (BJ) Jones, Jr. 44,964,804 10,240,447 1,795,532”
Material Agreements
Apogee Therapeutics, Inc. entered into Revenue Share Agreement with Annapurna Aggregator L.P., an affiliate of funds managed by Blackstone Life Sciences valued at $100.0 million upfront payment (effective 2026-05-26).
“On May 26, 2026 (the “Effective Date”), Apogee Therapeutics, Inc. (the “Company”) entered into a revenue participation right purchase and sale agreement (the “Revenue Share Agreement”) with Annapurna Aggregator L.P., an affiliate of funds managed by Blackstone Life Sciences (“BXLS”).”
Earnings Releases
Apogee Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 11, 2026, Apogee Therapeutics, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended March 31, 2026 (the “Earnings Press Release”).”
Material Agreements
Apogee Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC valued at $70.00 per share (effective 2026-03-24).
“On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the Underwriters named therein (the “Underwriters”), to issue and sell 5,000,000 shares of the Company’s common stock at a public offering price of $70.00 per share (the “Offering”).”
Lisa L. Bollinger was elected as Class II director at Apogee Therapeutics, Inc..
“the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) elected Lisa L. Bollinger, M.D. to serve as a Class II director of the Company”
Earnings Releases
Apogee Therapeutics, Inc. reported financial results for first quarter 2024.
“On May 13, 2024, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Earnings Releases
Apogee Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 13, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Earnings Releases
Apogee Therapeutics, Inc. reported financial results for second quarter 2023.
“On August 28, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.”
Mark C. McKenna was appointed as Chair of the Board at Apogee Therapeutics, Inc..
“On August 17, 2023, the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) appointed Mark C. McKenna as a member of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.